Friday, January 13, 2012 8:06:44 AM
QGEN was a much needed board: QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. As of September 30, 2011 , QIAGEN employed nearly 3,800 people in over 35 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.
Recent QGEN News
- QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows • Business Wire • 05/20/2026 08:05:00 PM
- QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA • Business Wire • 05/19/2026 08:05:00 PM
- QIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General Meeting • Business Wire • 05/12/2026 06:00:00 AM
- QIAGEN plant die Ernennung von Dr. Metin Colpan zum Ehrenvorsitzenden des Aufsichtsrats, setzt die Neuausrichtung der Aufsichtsratsstruktur fort und schlägt höhere Kapitalrückzahlungen auf der Hauptversammlung 2026 vor • Business Wire • 05/12/2026 06:00:00 AM
- QIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing • Business Wire • 05/07/2026 10:00:00 AM
- QIAGEN plant Einführung eines neuen, vollautomatisierten Sample-to-Insight-Workflows und eines KI-gestützten Tools zur Risikostratifizierung als Weiterentwicklung seines QuantiFERON-Tests zum Nachweis latenter Tuberkulose • Business Wire • 05/07/2026 10:00:00 AM
- QIAGEN meldet vollständige Ergebnisse für das erste Quartal 2026 • Business Wire • 05/06/2026 08:05:00 PM
- QIAGEN Reports Full Results for Q1 2026 • Business Wire • 05/06/2026 08:05:00 PM
- QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook • Business Wire • 04/27/2026 08:16:00 PM
- QIAGEN meldet vorläufige Ergebnisse für das erste Quartal 2026: Bereinigter Gewinn je Aktie entspricht bei gemischten Umsatztrends den Erwartungen; Jahresprognose 2026 aktualisiert • Business Wire • 04/27/2026 08:16:00 PM
- QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026 • Business Wire • 04/16/2026 08:05:00 PM
- QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel • Business Wire • 04/14/2026 08:05:00 PM
- Qiagen Announces Form 20-F Annual Report Filing for 2025 Results • Business Wire • 03/20/2026 11:30:00 AM
- QIAGEN stellt neue Daten zur Wirksamkeit von QuantiFERON in der Tuberkulose-Prävention vor • Business Wire • 03/19/2026 08:05:00 PM
- QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention • Business Wire • 03/19/2026 08:05:00 PM
- QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System • Business Wire • 03/10/2026 09:05:00 PM
- Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery • Business Wire • 02/19/2026 01:00:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/06/2026 05:08:56 PM
- QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars • Business Wire • 02/04/2026 09:05:00 PM
- QIAGEN übertrifft Prognose für das vierte Quartal 2025 dank seiner Wachstumsträger • Business Wire • 02/04/2026 09:05:00 PM
- QIAGEN präsentiert sein Hochdurchsatz-Automationssystem QIAsprint Connect für Labore weltweit auf der SLAS 2026 • Business Wire • 02/03/2026 09:05:00 PM
- QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026 • Business Wire • 02/03/2026 09:05:00 PM
- QIAGEN beruft Mark Stevenson in den Aufsichtsrat • Business Wire • 01/26/2026 09:05:00 PM
- QIAGEN Appoints Mark Stevenson to Supervisory Board • Business Wire • 01/26/2026 09:05:00 PM
- QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast • Business Wire • 01/19/2026 02:56:00 PM

